Arbeitsgruppe Kolon-/Rektum-/Dünndarmtumoren - Studien
| Metastasiertes kolorektales Karzinom - resektable Lebermetastasen | ||||
| AIO Joint Studie | Für weitere Zentren offen | zur Studie | ||
| DGAV/AIO: Perioperative FOLFOXIRI and bevacizumab compared with
postoperative FOLFOX and bevacizumab in patients with resectable liver
metastases from colorectal cancer - PERIMAX-trial |
||||
| AIO assoziierte Studie | Für weitere Zentren offen | zur Studie | ||
| LICC: L-BLP25 in Patienten mit kolorektalem Karzinom nach kurativer Lebermetastasenresektion – eine randomisierte, plazebokontrollierte, multizentrische, multinationale, doppelblinde Phase II Studie |
||||
| Weitere Informationen zu dieser Studie finden Sie hier! | ||||
| AIO Joint Studie | zur Studie |
|||
| Perioperative chemotherapy with FOLFOX plus Cetuximab versus adjuvant FOLFOX plus Cetuximab for patients with resectable liver metastases of colorectal carcinoma - PANTER-trial | ||||
| Metastasiertes kolorektales Karzinom – nicht-resektable Lebermetastasen |
||||
| AIO assoziierte Studie | Für weitere Zentren offen | zur Studie | ||
| CELIM 2- study: Cetuximab/FOLFIRI with or without oxaliplatin and FOLFOXIRI with or without bevacizumab in neoadjuvant treatment of non-resectable colorectal liver metastases | ||||
| AIO Studie | Für weitere Zentren offen | zur Studie | ||
| AIO-KRK-0109 – An open-label 2:1 randomized phase I/II study of panitumumab
plus FOLFOXIRI or FOLFOXIRI alone as first line treatment of patients
with non-resectable metastatic colorectal cancer and k-ras wild type (VOLFI) |
||||
| Metastasiertes kolorektales Karzinom - palliative Therapie 1st line | ||||
| AIO assoziierte Studie | Für weitere Zentren offen | zur Studie | ||
| AIO-KRK-0306 – Randomisierte Studie zur Wirksamkeit von FOLFIRI in Kombination mit Cetuximab vs. Bevacizumab in der Erstlinien-Behandlung des metastasierten kolorektalen Karzinoms | ||||
| AIO Studie | www.clinicaltrials.gov | zur Studie | ||
| AIO-KRK-0207: Randomized three arm phase III trial on induction treatment with a fluoropyrimidine-, oxaliplatin- and bevacizumab-based chemotherapy for 24 weeks followed by maintenance treatment with a fluoropyrimidine and bevacizumab vs. bevacizumab alone vs. no maintenance treatment and reinduction in case of progression for first-line treatment of patients with metastatic colorectal cancer | ||||
| AIO assoziierte Studie | Für weitere Zentren offen | zur Studie | ||
| AIO-KRK-0110 – Capecitabin plus Bevacizumab versus Capecitabin plus Irinotecan plus Bevacizumab als Erstlinien-Therapie beim metastasierten Kolorektalkarzinom | ||||
| AIO Studie | Für weitere Zentren offen | zur Studie | ||
| AIO-KRK-0112 - De-escalation of 1st-line chemotherapy with palliative intention in patients with metastatic CRC (KRAS wild type) with or without early tumor shrinkage (ETS) under FOLFIRI-Cetuximab therapy – A phase III study | ||||
| AIO Studie | Für weitere Zentren offen | zur Studie | ||
| AIO-KRK-0109 – An open-label 2:1 randomized phase I/II study of panitumumab plus FOLFOXIRI or FOLFOXIRI alone as first line treatment of patients with non-resectable metastatic colorectal cancer and k-ras wild type (VOLFI) | ||||
| AIO assoziierte Studie | Für weitere Zentren offen | zur Studie | ||
| AIO-KRK-0209: FOLFOX/bevacizumab with or without irinotecan in first-line treatment for metastatic colorectal cancer. | ||||
| AIO Joint-Studie | Für weitere Zentren offen | zur Studie | ||
| Resection of the primary tumour versus no resection prior to systemic therapy in patients with colon cancer and synchronous unresectable metastases (UICC stage IV) – A randomised controlled multicentre trial (SYNCHRONOUS-Trial) | ||||
| Metastasiertes kolorektales Karzinom – palliative Therapie, 2nd-line | ||||
| AIO Joint-Studie | Für weitere Zentren offen | zur Studie | ||
| AIO-KRK-0111: A multicenter, randomized phase II trial: BIBF 1120 vs. placebo in patients receiving oxaliplatin plus fluorouracil and leucovorin (mFOLFOX6) for advanced, chemorefractory metastatic colorectal cancer (mCRC) - TRICC-C | ||||
| Peritonealkarzinose | ||||
| AIO Joint-Studie | zur Studie | |||
| Multimodality treatment including pre- and postoperative systemic chemotherapy plus cetuximab, cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal carcinomatosis arising from wild type K-ras colon cancer: A prospective multicenter phase II study. (COMBATAC) | ||||
| Registerstudien | ||||
| AIO Joint-Studie | Für weitere Zentren offen | zur Studie | ||
| Tumorregister Kolorektales Karzinom (TKK): Erfassung der klinischen Behandlungsrealität für das kolorektale Karzinom in Deutschland | ||||